Dermatology Department, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
Dermatology Department, Nedlands, Sir Charles Gairdner Hospital, Western Australia, Australia.
Dermatol Ther. 2021 Jul;34(4):e14990. doi: 10.1111/dth.14990. Epub 2021 May 25.
Tocilizumab is a humanized monoclonal antibody to the interleukin-6 (IL-6) receptor which was first approved for use in refractory rheumatoid arthritis almost a decade ago. Since then, its use has expanded to a number of rheumatological and inflammatory conditions. In dermatology, off-label use of tocilizumab has been reported to be efficacious in morphoea, systemic sclerosis, psoriasis, atopic dermatitis, vitiligo, graft-versus-host disease, pyoderma gangrenosum, Behcet's disease, Schnitzler's syndrome, sarcoidosis, and cutaneous adverse reactions. That being said, the evidence demonstrating tocilizumab's efficacy in dermatology is predominantly low-level case-based evidence, and one must consider the potential for publication bias. In this review we will discuss the reported clinical applications of tocilizumab in dermatology, mechanisms of action, and the range of associated adverse effects (both cutaneous and non-cutaneous) that can occur. Additionally, we will discuss the role of tocilizumab in the management of COVID-19.
托珠单抗是一种针对白细胞介素-6（IL-6）受体的人源化单克隆抗体，近十年前首次获准用于治疗难治性类风湿关节炎。此后，其用途已扩展到许多风湿和炎症性疾病。在皮肤病学中，据报道，托珠单抗的超适应证使用在硬皮病、系统性硬化症、银屑病、特应性皮炎、白癜风、移植物抗宿主病、坏疽性脓皮病、贝赫切特病、 Schnitzler 综合征、结节病和皮肤不良反应中是有效的。话虽如此，但证明托珠单抗在皮肤病学中的疗效的证据主要是基于低水平的病例证据，因此必须考虑到发表偏倚的可能性。在这篇综述中，我们将讨论托珠单抗在皮肤病学中的报告临床应用、作用机制以及可能发生的一系列相关不良事件（包括皮肤和非皮肤）。此外，我们还将讨论托珠单抗在 COVID-19 管理中的作用。
